Pharmacogenetic Testing in the Outpatient Setting in Switzerland: A Descriptive Study Using Swiss Claims Data
In Switzerland, personalized pharmacotherapy has the potential to be improved, as only 0.09% of the studied population underwent PGx testing, despite 77.4% claiming PGx drugs.
Authors
- Nina L Wittwer (ORCID: https://orcid.org/0000-0002-3515-6043)
- Samuel Allemann (ORCID: https://orcid.org/0000-0003-4067-9401)
- Christoph Meier (ORCID: https://orcid.org/0000-0002-7120-6378)
- Henriette E. Meyer zu Schwabedissen (ORCID: https://orcid.org/0000-0003-0458-4579)
- Carola A. Huber (ORCID: https://orcid.org/0000-0002-2469-0435)
- Cornelia Schneider (ORCID: https://orcid.org/0000-0001-9628-691X)
Institutions
- University of Basel (CH)
- University Hospital of Basel (CH)
- Boston Collaborative Drug Surveillance Program (US)
- Helsana Group (Switzerland) (CH)
Publication Details
- Journal
- Drug Safety
- Published
- 2025-02-20
- DOI
- https://doi.org/10.1007/s40264-025-01522-z
- Citations
- 2
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 3.11
Funders
- Universität Basel